| Name | Title | Contact Details |
|---|
TermScout is a Denver-based legal-tech company that helps businesses review contracts smarter and faster.
Bringing over 75 years of combined industry experience, Incline P&C Group is the premier insurance program market services firm. Privately owned and operated with an exclusive focus on the program insurance market, the executive teams experience and expertise combined with effective underwriting discipline and risk management provides each client with various platforms and associated services to meet almost any need in the industry.
Maximus Partners is the leading professional services firm for growth-oriented organizations, with deep expertise in both CFO Advisory and Retained and Contingent Search services. We have worked alongside private equity investors and executive teams at PE-backed, privately-held and publicly-traded organizations to support hundreds of finance functions and evaluate and/or place thousands of professionals. This includes providing assessments of people, processes and technology, recommending and implementing solutions, and leading searches to hire key personnel to drive value creation.
In todays environment, it has never been easier to feel left behind. Clearoute is a consulting agency with expertise in helping businesses to develop and implement customized solutions that are tailored to their specific needs and goals. You need a strategic ally who can harness brand, performance-marketing, tech & innovation, sales, and finance to deliver significant results and exponential growth. See the future. We transform your complex business challenges into simple profitable solutions.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.